First-in-class anchored IL-12 immunotherapy increases immune cell infiltration into tumors while decreasing systemic toxicityHuman ANK-101, an IL-12- based anchored immunotherapy, will begin Phase 1 clinical studies in 2024CAMBRIDGE, Mass. (BUSINESS WIRE) Ankyra Therapeutics, a pre-clinical stage biotechnology com.
First-in-class anchored IL-12 immunotherapy increases immune cell infiltration into tumors while decreasing systemic toxicity Human ANK-101, an IL-12- based anchored immunotherapy, will begin Phase 1 clinical studies
Ankyra Therapeutics Presents Preliminary Phase 1 Canine Clinical Data Evaluating cANK-101 to Treat Advanced Malignant Melanoma in Dogs streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.